Research Studies

Browse Studies

Sage-718 DIMENSION

Enrolling
Not Enrolling
Conditions:
HD

Criteria

Ages
25-65
Cognition
any
Dyskinesias
any
Fluctuations
FALSE
Tremor
any
Gait
any
DBS
FALSE
Hallucinations
any

About this study

This phase 2 study seeks to evaluate the effect of the study drug SAGE-718 on the cognition of participants with premanifest or recent HD diagnosis. You can participate if you are between 25 to 65 years of age and have been diagnosed with early HD

Sustain our mission to enhance lives and outcomes through research

As we work to improve patient quality of life — for their entire lifespan — we seek partners to catapult our progress. With your philanthropic investment, we can expand the breadth and depth of our efforts in three critical areas: research, clinical care and education and training.

Support Us